Search results
Jemperli contends with blockbuster Keytruda in endometrial cancer
Clinical Trials Arena via Yahoo Finance· 1 hour agoThe sBLA approval is based on the success of the Phase III RUBY Part I trial and places Jemperli in...
U.K. Tests World-First Personalized Skin Cancer Vaccine
Forbes· 5 days agoBritish patients are trying a first-of-its-kind customized vaccine for skin cancer as part of a...
World-First mRNA Vaccine For Skin Cancer Commences Landmark Phase 3 Trial
IFLScience· 5 days agoA UK man has become one of the first to receive an experimental mRNA vaccine designed to prevent...
ESMO Recap: Adjuvant Vs. Neoadjuvant Therapy in Melanoma
Medscape· 6 days agoSapna Patel presented the first abstract, and it was a follow-up on some very nice work from the...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 6 days agoPhase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC ...
HOOKIPA advances HPV cancer trial with FDA nod By Investing.com
Investing.com· 6 days agoHOOKIPA Pharma Inc. (NASDAQ: HOOK), a clinical-stage biopharmaceutical company, has announced the...
NHS trials first personal skin cancer jab that can halve risk of death
The Telegraph via Yahoo News· 5 days agoIt is also undergoing early testing on other cancers. Around 70 Britons are set to take part in a...
H.C. Wainwright Cuts HOOKIPA Pharma Shares target on Narrower HB-200 Target Population By...
Investing.com· 5 days agoThe adjustment followed HOOKIPA Pharma's announcement regarding the trial design of a Phase 2/3...
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday? - Immutep (NASDAQ:IMMP)
Benzinga· 7 days agoImmutep releases preliminary results from TACTI-003 trial showing promising outcomes for first-line...
British man tests first personalised melanoma vaccine
BBC via Yahoo News· 5 days agoUniversity College London Hospitals (UCLH) doctors are giving it alongside another drug, ...